{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:32Z","timestamp":1761100532456},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":635,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2000,3,29]]},"abstract":"<jats:p>Transplant\u2010related morbidity and mortality remain a major problem following stem cell transplantation (SCT). The use of high\u2010dose single\u2010agent busulphan before allogeneic or autologous SCT may be a reasonable compromise between maintaining cytoreductive efficacy and minimizing toxicity in patients with chronic myeloid leukaemia (CML). Seventy patients with CML have received busulphan as the only cytoreductive therapy before SCT on 79 occasions. The probability of survival of the 14 allogeneic recipients (all of whom were undergoing a second transplant from the original donor) was 78% at 5 years. Sixty\u2010five autologous SCT were performed in 56 patients, of whom 40 were in late chronic phase. The actuarial 3\u2010year post\u2010autograft survival was 54% for these 56 first autografts. For patients in chronic phase, the 3\u2010year survival was 76% compared with 30% at 2 years for those with advanced phase disease. Busulphan therapy was well tolerated, and except for mild mucositis little toxicity was experienced. None of these patients developed hepatic veno\u2010occlusive disease (VOD). Nine patients (one allogeneic and eight autologous recipients) received several doses of an intravenous formulation of busulphan with very low toxicity. High\u2010dose busulphan alone appears sufficient to provide adequate cytoreduction and immunosuppression in second allogeneic transplants and is also effective as cytoreduction before autologous SCT in patients with CML.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2000.01905.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:23:03Z","timestamp":1047363783000},"page":"769-777","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High\u2010dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single\u2010centre experience"],"prefix":"10.1111","volume":"108","author":[{"given":"E.","family":"Olavarria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Szydlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"O'brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"53","article-title":"Bone marrow transplantation for patients with chronic myeloid leukaemia: T\u2010cell depletion reduces the incidence of graft\u2010versus\u2010host disease but increases the risk of leukaemic relapse","volume":"1","author":"Apperley J.F.","year":"1986","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.10.3211.3211"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V84.3.724.724","article-title":"Autografting with cultured marrow in chronic myeloid leukaemia: results of a pilot study","volume":"84","author":"Barnett M.J.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(94)90111-2"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb00223.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood.V93.5.1534","article-title":"Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia","volume":"83","author":"Carella A.M.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06397.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.3068.3068"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701026"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V88.2.714.bloodjournal882714","article-title":"Relapse after non\u2010T\u2010cell\u2010depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft\u2010versus\u2010host disease are protective","volume":"88","author":"Enright H.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_6_15_1","first-page":"509","article-title":"Bone marrow transplantation for chronic myeloid leukemia: long\u2010term results","volume":"12","author":"Gratwohl A.","year":"1993","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb06118.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054777"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03255.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2462.2462"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700994"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92589-5"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08621.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1224"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.V91.3.1091","article-title":"Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia","volume":"91","author":"O'brien S.G.","year":"1998","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_27_1","first-page":"39","article-title":"Autografting in chronic phase CML using PBPCs mobilized by intermediate\u2010dose chemotherapy (Abstract)","volume":"89","author":"O'brien S.G.","year":"1995","journal-title":"British Journal of Haematology"},{"key":"e_1_2_6_28_1","first-page":"804","article-title":"Autografting for CML using bone marrow purged with MYB antisense oligonucleotide (Abstract)","volume":"23","author":"O'brien S.G.","year":"1995","journal-title":"Experimental Hematology"},{"key":"e_1_2_6_29_1","first-page":"684a","article-title":"A multiple\u2010dose phase I pharmacokinetic study of intravenous busulfan as myeloablation prior to bone marrow transplantation","volume":"92","author":"Olavarria E.C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_30_1","first-page":"407","article-title":"Autologous stem cell transplantation in chronic myelogenous leukaemia: a retrospective analysis of the European Group for Bone Marrow Transplantation","volume":"14","author":"Reiffers J.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.11.3377.3377"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00709.x"},{"issue":"3","key":"e_1_2_6_33_1","first-page":"S55","article-title":"Intensive treatment in order to minimise the Ph positive clone in chronic myelogeneic leukaemia (CML)","volume":"14","author":"Simonsson B.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_34_1","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulphan pharmacokinetics","volume":"16","author":"Slattery J.T.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation with cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin S.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05236.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03169.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01905.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01905.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2000.01905.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:04:11Z","timestamp":1698563051000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2000.01905.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,29]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,3,29]]}},"alternative-id":["10.1046\/j.1365-2141.2000.01905.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01905.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,29]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}